share_log

Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock

Benzinga ·  Sep 25 01:01

7 analysts have expressed a variety of opinions on Zevra Therapeutics (NASDAQ:ZVRA) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings61000
Last 30D21000
1M Ago20000
2M Ago10000
3M Ago10000

Analysts have set 12-month price targets for Zevra Therapeutics, revealing an average target of $19.71, a high estimate of $25.00, and a low estimate of $15.00. This current average reflects an increase of 8.48% from the previous average price target of $18.17.

1727197271_0.png

Exploring Analyst Ratings: An...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment